School of Medicine


Showing 81-90 of 639 Results

  • Alma-Martina Cepika

    Alma-Martina Cepika

    Instructor, Pediatrics - Stem Cell Transplantation

    BioDr. Cepika is an immunologist with an extensive background in translational research, autoimmunity, autoinflammation, and human systems immunology. Her goal is to understand the mechanisms governing immunological tolerance, and to leverage this knowledge to cure currently incurable diseases.

    Dr. Cepika received her MD degree and a PhD in Immunology from the University of Zagreb School of Medicine in Croatia. There, she focused on the immunomonitoring of patients with lupus, identifying how circulating DNA levels changed with therapy. Subsequently, she joined the lab of Dr. Virginia Pascual at the Baylor Institute for Immunology Research in Dallas, Texas. Dr. Pascual had previously discovered that IL-1beta is a key pathogenic player in systemic juvenile idiopathic arthritis (sJIA), but the immune alterations contributing to IL-1beta-mediated inflammation remained unknown. To address this, Dr. Cepika developed a 3D in vitro stimulation assay to evaluate immune responses of blood leukocytes of pediatric sJIA patients. In combination with integrated bioinformatics analysis, this approach identified aberrant cellular responses, transcriptional pathways and genes that shed new light on immune dysregulation in sJIA. This assay (tollgene.org) can be further applied to dissect underlying immunopathogenic mechanisms in many human disorders.

    Currently, Dr. Cepika is an Instructor in the Pediatric Division of Stem Cell Biology and Regenerative Medicine at Stanford University School of Medicine. There, she is working to uncover the underlying molecular mechanisms that govern the differentiation and function of antigen-inducible regulatory T cells called type 1 regulatory T (Tr1) cells, and use this knowledge to design Tr1 cell-based therapies to improve the outcomes of patients with cancer, autoimmunity, or receiving allogeneic cell or organ transplants.

  • Anne Lynn S. Chang, MD

    Anne Lynn S. Chang, MD

    Professor of Dermatology

    Current Research and Scholarly InterestsI have two main research interests:
    1) to better understand and treat patients with aggressive basal and squamous cell carcinomas
    2) to better understand the genetic and epigenetic mechanisms of healthy human skin aging and to translate these insights into better care of skin diseases enriched in older patients particularly skin cancer and rosacea

  • Howard Y. Chang, MD, PhD

    Howard Y. Chang, MD, PhD

    Virginia and D. K. Ludwig Professor of Cancer Research, Professor of Genetics and, by courtesy, of Pathology

    Current Research and Scholarly InterestsOur research is focused on how the activities of hundreds or even thousands of genes (gene parties) are coordinated to achieve biological meaning. We have pioneered methods to predict, dissect, and control large-scale gene regulatory programs; these methods have provided insights into human development, cancer, and aging.

  • James K. Chen

    James K. Chen

    Jauch Professor and Professor of Chemical and Systems Biology, of Developmental Biology and of Chemistry

    Current Research and Scholarly InterestsOur laboratory combines chemistry and developmental biology to investigate the molecular events that regulate embryonic patterning, tissue regeneration, and tumorigenesis. We are currently using genetic and small-molecule approaches to study the molecular mechanisms of Hedgehog signaling, and we are developing chemical technologies to perturb and observe the genetic programs that underlie vertebrate development.

  • Michelle M. Chen, MD, MHS

    Michelle M. Chen, MD, MHS

    Assistant Professor of Otolaryngology - Head & Neck Surgery (OHNS)

    BioDr. Chen is a fellowship-trained head and neck surgical oncologist with a board certification in otolaryngology and a clinical assistant professor with the Stanford School of Medicine Department of Otolaryngology.

    Her practice focuses on the treatment of cancers that affect the head and neck. She has received additional training in microvascular reconstruction and transoral robotic surgery.

    Dr. Chen has an active lab involved in head and neck cancer health services research and her work has appeared in numerous journals, including The Journal of the American Medical Association, Cancer, Journal of the National Cancer Institute, and Journal of Clinical Oncology. She has also authored chapters in textbooks on head and neck cancer treatment.

    Dr. Chen is a member of the American Academy of Otolaryngology—Head & Neck Surgery (AAOHNS) and the American Head & Neck Society.

  • Yiyun Chen

    Yiyun Chen

    Postdoctoral Scholar, Stanford Cancer Center

    BioYiyun Chen, Ph.D. is a Postdoctoral Fellow at Professor Crystal Mackall’s group at Stanford Cancer Institute.

    Dr. Chen studied biochemistry and structural biology in her undergraduate and master trainings at The Hong Kong University of Science and Technology, where she eventually obtained her Ph.D. degree in computational biology under the supervision of Professor Jiguang Wang. During her Ph.D. training, she has developed her skill sets in analyzing and integrating various types of patient-derived sequencing data, published three first-author and four co-author papers, and received two awards for top postgraduate students. Through interdisciplinary collaborations with cancer biologist and clinicians in US and Asia, her work has uncovered tumor-specific immune cell subtypes and novel noncoding RNAs and generated new insights into precision medicine in glioma, lymphoma and gastric cancer.

    Applying her expertise in computational cancer biology and immunology, her current research is focused on identifying molecular mechanisms that contribute to the clinical outcomes of patients undergoing CAR-T immunotherapy. At Mackall Lab, she will contribute to tailoring computational pipelines for profiling the spatiotemporal dynamics of the tumor and immune microenvironment and translate new discoveries into cancer therapeutics.